sattva neelapu, md, regarding the zuma-1 two-year follow-up study in dlbcl
Published 5 years ago • 47 plays • Length 1:41
Download video MP4
Download video MP3
Similar videos
-
1:18
sattva neelapu, md, tells us about the results of the zuma-1 study in dlbcl presented at ash 2019
-
1:23
sattva neelapu, md, discusses efficacy results of the zuma-1 trial
-
1:17
sattva neelapu, md, explains what the results of zuma-1 mean to dlbcl patients
-
0:46
key takeaway from 2-year follow-up data of zuma-1 trial in large b-cell lymphoma
-
2:13
sattva neelapu | ash 2018 | results from the two-year follow-up of zuma-1
-
2:32
zuma-1 update: durable survival in r/r dlbcl patients treated with axi-cel
-
2:24
dr. neelapu on axi-cel in the zuma-1 trial for refractory aggressive non-hodgkin lymphoma
-
2:02
dr. neelapu on updated zuma-1 findings in non-hodgkin lymphoma
-
14:59
lymphoma cytological grading
-
2:22
swami vivekananda explains importance of sattvic vegetarian food | benefits of cruel-free pure food
-
47:23
lymphoplasmacytic neoplasms: cases and differentials
-
2:03
long-term follow-up results from the zuma-1 trial in non-hodgkin lymphoma
-
1:33
sattva neelapu, md, on real-world experience & clinical studies examining axicabtagene ciloleucel
-
2:48
zuma-1: safety and efficacy of axicabtagene in refractory non-hodgkin lymphoma patients
-
1:34
sattva neelapu, md, speculates on the future of first-line car t-cell therapy in lymphoma
-
1:47
meet lymphoma specialist sattva neelapu, m.d.
-
2:17
zuma-12: axicabtagene ciloleucel as a first-line therapy in patients with high-risk lbcl
-
1:44
comparison of zuma-1 and scholar-1 outcomes
-
8:01
high-risk lymphoma: the zuma-1 and scholar-1 trials
-
1:37
sattva neelapu, md, considers the use of axicabtagene ciloleucel with elderly lymphoma patients
-
3:09
sattva neelapu, md, discusses advancements in the management of car t-cell therapy aes
-
1:19
sattva neelapu, md, on novel agents and up-front approaches showing efficacy in lymphomas
Clip.africa.com - Privacy-policy